Creatine kinase elevation associated with 5-fluorouracil and levamisole therapy for carcinoma of the colon - A case report

被引:0
作者
Cersosimo, RJ
Lee, JF
机构
[1] VET ADM MED CTR,DEPT HEMATOL & MED ONCOL,BOSTON,MA
[2] BOSTON UNIV,SCH MED,BOSTON,MA 02118
关键词
colon carcinoma; creatine kinase; enzymes; fluorouracil; levamisole;
D O I
10.1002/(SICI)1097-0142(19960401)77:7<1250::AID-CNCR4>3.0.CO;2-M
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
BACKGROUND. There have been no reports of creatine phosphokinase (CK) elevation during levamisole administration. There is only one prior report of CK elevation of noncardiac origin associated with 5-fluorouracil. METHODS. A 41-year-old man was diagnosed with Stage B2 colon carcinoma and underwent extensive surgical resection. Adjuvant therapy with 5-fluorouracil and levamisole was initiated after surgery. A complete hematologic and chemistry profile was obtained during weekly clinic visits. RESULTS. The patient's serum CK levels were normal prior to the initiation of chemotherapy but began to rise after 4 weeks of therapy, Isoenzyme analysis revealed that the CK was 100% from skeletal muscle. When the CK level surpassed 1,000 U/L, chemotherapy was discontinued. The CK levels began to decline immediately, falling to normal within 2 months. All attempts to identify a known cause of the enzyme elevation were negative. CONCLUSIONS. The temporal relationship between chemotherapy administration, enzyme elevation, and the rapid fall in enzyme levels upon discontinuation of treatment argue strongly in favor of chemotherapy as the etiology of CK elevation in this patient. (C) 1996 American Cancer Society.
引用
收藏
页码:1250 / 1253
页数:4
相关论文
共 18 条
[1]   FLUOROURACIL CARDIOTOXICITY [J].
ANAND, AJ .
ANNALS OF PHARMACOTHERAPY, 1994, 28 (03) :374-378
[2]  
COLLINS C, 1987, CANCER TREAT REP, V71, P733
[3]  
DENT RG, 1975, LANCET, V1, P347
[4]  
*JANSS PHARM, 1994, ERG PACK INS
[5]   CLINICAL CARDIOTOXICITY OF 5-FLUOROURACIL [J].
KEEFE, DL ;
ROISTACHER, N ;
PIERRI, MK .
JOURNAL OF CLINICAL PHARMACOLOGY, 1993, 33 (11) :1060-1070
[6]  
KOPPEL C, 1989, MED TOXICOL ADV DRUG, V4, P108
[7]   LEVAMISOLE AND FLUOROURACIL FOR ADJUVANT THERAPY OF RESECTED COLON-CARCINOMA [J].
MOERTEL, CG ;
FLEMING, TR ;
MACDONALD, JS ;
HALLER, DG ;
LAURIE, JA ;
GOODMAN, PJ ;
UNGERLEIDER, JS ;
EMERSON, WA ;
TORMEY, DC ;
GLICK, JH ;
VEEDER, MH ;
MAILLIARD, JA .
NEW ENGLAND JOURNAL OF MEDICINE, 1990, 322 (06) :352-358
[8]   FLUOROURACIL PLUS LEVAMISOLE AS EFFECTIVE ADJUVANT THERAPY AFTER RESECTION OF STAGE-III COLON-CARCINOMA - A FINAL REPORT [J].
MOERTEL, CG ;
FLEMING, TR ;
MACDONALD, JS ;
HALLER, DG ;
LAURIE, JA ;
TANGEN, CM ;
UNGERLEIDER, JS ;
EMERSON, WA ;
TORMEY, DC ;
GLICK, JH ;
VEEDER, MH ;
MAILLIARD, JA .
ANNALS OF INTERNAL MEDICINE, 1995, 122 (05) :321-326
[9]   HEPATIC TOXICITY ASSOCIATED WITH FLUOROURACIL PLUS LEVAMISOLE ADJUVANT THERAPY [J].
MOERTEL, CG ;
FLEMING, TR ;
MACDONALD, JS ;
HALLER, DG ;
LAURIE, JA .
JOURNAL OF CLINICAL ONCOLOGY, 1993, 11 (12) :2386-2390
[10]  
MOSSERI M, 1993, CANCER RES, V53, P3028